Genotyping of Human Papillomavirus

Similar documents
HIV Diagnostic Tests. HIV Testing Algorithm at SydPath (National Reference Laboratory)

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

ABIOpure TM Total RNA (version 2.0)

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

For Research Use Only Ver

PROTOCOL. SOD2 Protein Quantity Microplate Assay Kit. MS746 Rev.0 DESCRIPTION INTRODUCTION

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Study Design Open, three arm-stratified, non-randomized, prospective, multicentric study

CDC Influenza Division Key Points MMWR Updates February 20, 2014

Annex III. Amendments to relevant sections of the Product Information

NHAIS SIS Communication

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

Data Fusion for Predicting Breast Cancer Survival

Section IA-Introduction

Reducing Cervical Cancer in the Sololá Department of Guatemala

CONTENTS. 1. NEO-SENSITABS TM a. Susceptibility Testing b. Antifungal c. Veterinary 2. ACCESSORIES. 3. DIATABS TM Identification of Bacteria and Fungi

Know for sure! Your Power for Health. PapilloCheck and PapilloCheck high-risk HPV-Genotyping: The Clear Edge in Early Detection of Cervical Cancer.

FTD RESEARCH: The Value of Studies and Opportunities for Involvement

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

Volume Measurement at CT

Referral Criteria: Inflammation of the Spine Feb

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

US Public Health Service Clinical Practice Guidelines for PrEP

Health Science Ch. 16 Cancer Lecture Outline

LYME DISEASE (taken from 6/20/13)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Protocol. Preparation Protocol for the Non-Targeted Vevo MicroMarker Contrast Agent

INFERTILITY DIAGNOSIS

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

EAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL


Patrick J McGahan, MD Orthopaedic Surgeon Specializing in Sports Medicine/Shoulder Reconstruction Surgery Instructions Hip

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion

Be sure! Your Power for Health. PelvoCheck CT/NG Your test kit for Chlamydia trachomatis screening and Neisseria gonorrhoeae infections

Safety of HPV vaccination: A FIGO STATEMENT

SQA-VISION VALIDATION REPORT

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

SUBSPECIALIST TRAINING PROGRAMME in GYNAECOLOGICAL ONCOLOGY

Chapter 6: Impact Indicators

Institutions. Residential care homes in the UK, refugee camps in some parts of the world.

International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma 1

Pandemic H1N1 2009: DrillSafe Update. David Blizzard BD Manager, Energy Mining and Infrastructure

PROTOCOL 1850 Millrace Drive, Suite 3A Eugene, Oregon

ACRIN 6666 Screening Breast US Follow-up Assessment Form

Directory of Laboratory Services

EMEA DICOMBurner solution EMEA DICOMBurner solution

Frequently Asked Questions: IS RT-Q-PCR Testing

DHMO Provider Choice Product Exit, 2-50 and 51+

23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)

Before Your Visit: Mohs Skin Cancer Surgery

Medical Student Immunization Requirements

Related Policies None

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

2017 CMS Web Interface

FDA Dietary Supplement cgmp

Triumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media

Humanities and Social Sciences Division. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses

Significance of Chronic Kidney Disease in 2015

INSTRUCTIONS FOR USE ZINBRYTA (zin-bry-tuh) (daclizumab) Injection, for Subcutaneous Use Single-Dose Prefilled Syringe 150 mg

President Chirac understood that fighting disease is not just health systems and hospitals, it is about people. We must place people at the centre.

MEDICATION GUIDE. (fingolimod) capsules

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.

Head and neck cancers are often treated with radiotherapy. Radiotherapy can lead to faster rates of tooth decay and poor healing in the mouth.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

2018 Medical Association Poster Symposium Guidelines

WHAT IS HEAD AND NECK CANCER FACT SHEET

Chapter 5 Anxiety Disorders

MEDICATION GUIDE. Reference ID:

BRCA1 and BRCA2 Mutations

Package leaflet: Information for the user. Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Solution for injection dalteparin sodium

LTCH QUALITY REPORTING PROGRAM

Standard Operating Procedures for Quantitative HIV-1 viral load testing using GeneXpert technology. June 2015

RoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

2. How are screening and diagnostic mammograms different?

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium

Patrick J McGahan, MD Orthopaedic Surgeon Specializing in Sports Medicine/Shoulder Reconstruction

PART III: CONSUMER INFORMATION

Extended G/L Segment Codes

The Cell Cycle & Cellular Division

Protocol Abstract and Schema

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

OTHER AND UNSPECIFIED DISORDERS

BSUG Database User Update Document June 15 th 2015

HPV VACCINATION IN SANDYFORD SERVICES

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE

PATIENT INFORMATION. (methotrexate) injection, for subcutaneous use

2. What is SO 2? 3. The World Health Organization states that air pollution.

INCLUDED. Oral Care Control Device Interchangeable Mouth Tray Power Supply Power Cable Storage Case Silicone Cleaning Cover (Do Not Discard)

MEDICATION GUIDE. (Interferon alfa-2b)

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate

How to Get Set Up and Running with NDepend

Refining Blood Collection Techniques to Improve Animal Welfare and Sample Quality

EAST VALLEY DERMATOLOGY CENTER

Instructions for Use INTRON A (In-tron-aye) (Interferon alfa-2b, recombinant) Powder for Solution

REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES

Transcription:

VisinArray Arrays fr DNA analysis Gentyping f Human Papillmavirus mplete C r u Y frm n i t u l S ctin a r t x E DNA sis! y l a n A t Simultaneus Detectin f 41 HPV Types High Sensitivity Easy t Handle

Imprtance f HPV Testing The human papillmavirus (HPV) has been cnclusively identified as the majr risk factr fr cervical cancer. It is the third mst cmmn cancer in wmen wrldwide, with an estimated number f 530,000 new cases and 280,000 deaths each year. Over the last years the relevance f HPV in the histry f rpharyngeal cancers has becme mre and mre imprtant which is indicated by a dramatically risen number f cancers f the ral cavity and pharynx linked t HPV. Cervical Cancer Prgressin Initial HPV infectin requires virin integratin int the basal epithelial cells. Whereas mst HPV infectins are transient and are cleared by the immune system, infectin with HPV high risk types may lead t cancer when infectin persists. Expsure Transient Infectin Persistant Infectin Infectin Prgressin Invasin Nrmal Cervix Clearance Prductive Infectin Regressin Precursr Lesin Cancer Cytlgy? Cytlgy? HPV Gentype? Cytlgy? HPV Gentype? Cytlgy? HPV Gentype? Duratin 0 16-18 mnths 24 mnths 7-15 years VisinArray HPV Chip Fast and Reliable Gentyping The VisinArray HPV Chip 1.0 is intended t be used with the VisinArray Analysis Package fr the qualitative detectin and gentyping f PCR amplificates f 41 clinically relevant HPV gentypes. + 6 11 16 18 26 High Risk HPV Types detected by the VisinArray HPV Chip 31 33 34 35 39 40 42 43 44 45 51 52 53 54 55 56 57 58 59 61 62 66 67 68a 68b 69 70 72 73 81 82 82 IS39 MM4 83 84 90 91 35 34 33 31 26 18 16 11 6 + 54 53 52 51 45 44 43 42 40 39 16 18 31 33 35 39 45 51 52 56 58 59 Prbably High Risk HPV Types detected by the VisinArray HPV Chip 26 34 53 66 67 68a 68a 67 66 62 61 59 58 57 56 55 81 73 72 70 69 68b 91 90 84 83 82 MM4 82 IS39 68b 69 70 73 82 (IS39) 82 (MM4) Lw Risk HPV Types detected by the VisinArray HPV Chip 6 11 40 42 43 44 54 55 57 High Risk Prbably High Risk Lw Risk Guide Dts/Psitive Cntrl 61 62 72 81 (CP8304) 83 (MM7) 84 (MM8) 90 91 References: Bumba LM, et al. (2014) BMC Public Health 14: 1320 Clmb N, et al. (2012) Ann Oncl 23 Suppl 7: vii27-32 Crw JM, et al. (2012) Nature 488: S2-S3 IARC (2012) Bilgical Agents. IARC Mngr Eval Carcing Risks Hum, 100B: 1-441 Pljak M, et al. (2016) J Clin Virl 76 Suppl 1: S3-S13 http://glbcan.iarc.fr

1. Sample Cllectin Fr the detectin f HPV gentypes with the VisinArray HPV system the fllwing raw material can be used fr DNA extractin: Frmalin-fixed, paraffin-embedded (FFPE) tissue samples Cervical swab/brush specimen Liquid based cytlgy specimen (ThinPrep ) 2. Detectin & Differentiatin f 41 HPV Types Step 1: Amplificatin and Labeling in a PCR Bitinylated primers are used t amplify and label different sectins f the L1 regin f the HPV genme. The human HLA-DQA1 gene is als amplified and serves as a PCR psitive cntrl and as a genmic cntrl. Step 2: Hybridizatin n the Glass Chip After amplificatin, the bitinylated sequences hybridize t cmplementary DNA capture sequences n the glass chip. Step 3: Detectin and Visualizatin Specifically bund and bitinylated sequences are visualized by secndary marking with a streptavidinperxidase cnjugate and a staining with tetramethylbenzidine. After clr develpment, evaluatin is perfrmed using the VisinArray Analyzer Sftware.

3. Wrkflw Schedule This is a cndensed prtcl fr the VisinArray methd and shuld nt replace the instructin fr use! 0 Min. PCR Fr the PCR the VisinArray Primer Kit is used The master mix is prepared by using the dntp/dutp Slutin, HPV Primer Mix, VisinArray PreCise Taq Plymerase, VisinArray Uracil-DNA Glycsylase and the crrespnding reactin buffers Alternatively: The VisinArray HPV PreCise Master Mix can be used DNA sample is added t the master mix Hybridizatin PCR prduct and Hybridizatin Slutin are mixed well Mix is applied nt the VisinArray Chip 30 Min. Duratin: 30 min Stringency Wash Unbund DNA fragments are remved using 1x Wash Buffer Drying f VisinArray Chip by centrifugatin Duratin: 2 min Detectin Marking f bitinylated sequences using the Detectin Slutin Visualizatin is perfrmed by applying the Blue Spt Slutin 50 Min. Duratin: 17 min Wash Remving f the Blue Spt Slutin by washing with 1x Wash Buffer Drying f VisinArray Chip by centrifugatin Duratin: 2 min Analysis 60 Min. Chips are scanned with VisinArray Scanner 8100 Autmated analysis is perfrmed by using the VisinArray Analyzer Sftware Duratin: 10 min Quick & easy 1 hur prtcl Autmated user-friendly evaluatin within a few minutes

HPV Tests in Cmparisn Assay Gentyping C-infectin N. f CE-IVD HPV Types (cpies/reactin) Anyplex TM II HPV28 Detectin 28 50 Cervista HPV HR 14 1.250 CLART HPV (3, 4) 35 10 HPV 16 + 18 HPV 16 + 18 14 150 cpies/ml digene HC2 HPV DNA Test 18 3100 INNO-LiPA HPV Gentyping Extra II 32 20 41 50 cbas HPV Test VisinArray * Sensitivity data are accrding t the respective instructin fr use VisinArray At a Glance Simultaneus gentyping f 41 different HPV types all certified fr in vitr diagnstic use All capture sequences and psitive cntrls are set up n the VisinArray Chip as duplicates High sensitivity and specificity Quick & easy 1 hur prtcl Autmated evaluatin using the VisinArray Analyzer Sftware simple visualizatin & quick analysis in just a few minutes Sensitivity*

VisinArray Arrays fr DNA analysis VisinArray HPV Chips Prd. N. Prduct Tests VA-0001-10 VisinArray HPV Chip 1.0 10 Incl. 10 pieces VA-0001-50 VisinArray HPV Chip 1.0 50 Incl. 5x 10 pieces VA-0002-10 VisinArray HPV High Risk Chip 1.0 10 Incl. 10 pieces VA-0002-50 VisinArray HPV High Risk Chip 1.0 50 Incl. 5x 10 pieces VisinArray DNA Extractin, PCR, and Detectin Prd. N. Prduct Tests VI-0001-50 VisinArray FFPE DNA Extractin Kit 50 Incl. Paraffin Disslver; Tissue Lysis Buffer; Decrsslink Buffer; DNA Wash Buffer; Prteinase K; Prteinase K Buffer; Elutin Buffer; Clumns; Cllectin Tubes VI-0002-50 VisinArray Cytlgy DNA Extractin Kit 50 Incl. Pre-Lysis Buffer; Cell Lysis Buffer; DNA Wash Buffer; Prteinase K; Prteinase K Buffer; Elutin Buffer; Clumns; Cllectin Tubes Prd. N. Prduct Tests VP-0001-50 VisinArray HPV Primer Kit 50 Incl. HPV Primer Mix; dntp/dutp Slutin VE-0001-100 VisinArray PreCise Taq DNA Plymerase 100 Incl. VisinArray PreCise Taq DNA Plymerase, Reactin Buffer, 10x; PreCise MgCl 2, 25 mm VE-0002-100 VisinArray Uracil-DNA Glycsylase 100 Incl. VisinArray Uracil- DNA Glycsylase (UDG), UDG Reactin Buffer, 10x ES-0007-50 VisinArray HPV PreCise Master Mix 50 Prd. N. Prduct Tests VK-0003-50 VisinArray Detectin Kit 50 Incl. Hybridizatin Slutin, 1 ml; Detectin Slutin, 5 ml; Blue Spt Slutin, 5 ml; 100x Wash Buffer, 250 ml E-4051-1 Mini Slide Centrifuge VisinArray Analysis Package Prd. N. E-4060-1 Prduct VisinArray Analysis Package Incl. Scanner 8100; Slide Hlder; Hand Scanner; PC with preinstalled VisinArray Analyzer Sftware; USB-Hub; External Hard Drive; Cmputer Muse nly available in certain cuntries. All ther cuntries research use nly! Please cntact yur lcal dealer fr mre infrmatin. M-5099-9-2017 Manufactured by: 42 life sciences GmbH & C. KG Fischkai 1 27572 Bremerhaven Germany Distributed by: ZytVisin GmbH Fischkai 1 27572 Bremerhaven Germany www.zytvisin.cm inf@zytvisin.cm VisinArray is a trademark f 42 life sciences GmbH & C. KG